SCHEMBL5097704

SCHEMBL5097704

CCc1nc2cc(C)nn2c(N)c1CC(CC)CC

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.38
▸ MAOB P27338 1/20 0.35
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ NPC1 O15118 2/20 0.33
▸ RAB9A P51151 2/20 0.33
▸ HPGD P15428 2/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ TP53 P04637 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ DPP4 P27487 1/20 0.33
▸ PIK3CG P48736 1/20 0.32
▸ PKM P14618 1/20 0.32
▸ POLB P06746 1/20 0.32
▸ AURKA O14965 1/20 0.32
▸ KDR P35968 1/20 0.32
▸ AURKB Q96GD4 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.31
▸ HSD17B10 Q99714 1/20 0.31
▸ GAA P10253 1/20 0.30
▸ CRHR1 P34998 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5091110 0.83 KDM4E (0.35) KDM4EMAOBSMN1; SMN2NPC1RAB9A
SCHEMBL5103686 0.78 GCGR (0.39) KDM4EMAOBSMN1; SMN2NPC1RAB9A
SCHEMBL5095285 0.78 GCGR (0.39) KDM4EMAOBSMN1; SMN2NPC1RAB9A
SCHEMBL5097338 0.74 KDM4E (0.35) KDM4EMAOBSMN1; SMN2NPC1RAB9A
SCHEMBL14182277 0.73 KDM4E (0.43) KDM4EMAOBSMN1; SMN2NPC1RAB9A
SCHEMBL5097742 0.73 DHFR (0.36) KDM4ESMN1; SMN2NPC1RAB9AHPGD
SCHEMBL5095251 0.73 KDM4E (0.39) KDM4ESMN1; SMN2NPC1RAB9AHPGD
SCHEMBL10623166 0.72 KDM4E (0.42) KDM4EMAOBSMN1; SMN2NPC1RAB9A
SCHEMBL4892593 0.72 KDM4E (0.42) KDM4EMAOBSMN1; SMN2NPC1RAB9A
SCHEMBL14113724 0.71 KDM4E (0.41) KDM4EMAOBSMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080207455-A1 5,6-Dialkyl-7-Aminoazolopyrimidines, Their Preparation and Their Use for Controlling Harmful Fungi, and Compositions Comprising These Compounds BASF AKTINGESELLSCHAFT (DE) 2008-08-28 — — US claimed
EP-1856118-A1 5,6-DIALKYL-7-AMINO-AZOLOPYRIMIDINES, METHODS FOR THE PRODUCTION THEREOF, USE THEREOF FOR CONTROLLING HARMFUL FUNGI, AND SUBSTANCES CONTAINING THE SAME BASF AKTIENGESELLSCHAFT (DE) 2007-11-21 — — EP claimed
WO-2006092411-A1 5,6-DIALKYL-7-AMINO-AZOLOPYRIMIDINES, METHODS FOR THE PRODUCTION THEREOF, USE THEREOF FOR CONTROLLING HARMFUL FUNGI, AND SUBSTANCES CONTAINING THE SAME BASF AKTIENGESELLSCHAFT (DE) 2006-09-08 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207455-A1 5,6-Dialkyl-7-Aminoazolopyrimidines, Their Preparation and Their Use for Controlling Harmful Fungi, and Compositions Comprising These Compounds CBX7, ERG28, HDHD5 KDM4E 560/4885MAOB 2459/4885SMN1; SMN2 4481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback